Introduction: Solving the Digital Eye Strain and Meibomian Gland Dysfunction Epidemic For millions of individuals suffering from dry eye disease (DED), digital eye strain (computer vision syndrome due to prolonged screen use (computers, smartphones, tablets, e-readers, gaming), decreased blink rate (20% vs 80% normal), incomplete blinking, evaporative tear loss), contact lens-induced dryness, meibomian gland dysfunction (MGD) (oil gland obstruction), Sjögren's syndrome (autoimmune), blepharitis, allergic conjunctivitis, and refractive surgery (LASIK, PRK) post-operative dry eye, artificial tears provide symptomatic relief. Dry or tired eye drops (ophthalmic lubricants, artificial tears) are sterile formulations (eye drops, gels, ointments, inserts) containing demulcents (polyvinyl alcohol (PVA), povidone (PVP), polyethylene glycol (PEG), propylene glycol, hypromellose (HPMC), carboxymethylcellulose (CMC), hydroxypropyl cellulose (HPC), dextran, glycerin, mineral oil, light mineral oil), electrolytes (sodium, potassium, calcium, magnesium, bicarbonate, chloride, phosphate), humectants (sodium hyaluronate (hyaluronic acid), glycerin), viscosity agents (carbomer 940), emulsifiers (polysorbate 80), and preservatives (benzalkonium chloride (BAK), polyquaternium-1, sodium perborate, oxychloro complex, sodium chlorite) or preservative-free (single-dose units). According to the latest industry report released by Global Leading Market Research Publisher QYResearch, "Dry or Tired Eye Drops - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032", the global market for Dry or Tired Eye Drops was estimated to be worth US millionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032. Dry or tired eye drops are over-the-counter (OTC) or prescription solutions used to relieve the discomfort associated with dry eyes. Dry eyes occur when the eyes do not produce enough tears or when the tears evaporate too quickly, resulting in symptoms such as itchiness, redness, irritation, burning, or a gritty feeling in the eyes. The primary function of these drops is to provide lubrication and moisture to the eyes, supplementing the natural tear film and alleviating dryness. Dry eye drops typically contain a combination of water, salts, and other components that mimic the composition of natural tears. Some may also contain electrolytes, hyaluronic acid, glycerin, or oils to enhance lubrication. These drops help reduce irritation, redness, and discomfort associated with dry eyes caused by factors like environmental conditions, prolonged screen use, contact lens wear, certain medications, or aging. There are various types of dry eye drops available, including preservative-free options for those with sensitive eyes and those needing to use drops frequently. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/5974279/dry-or-tired-eye-drops 1. Product Type Deep Dive: Eye Drops vs. Eye Gels vs. Ointments Unlike oral medications, dry or tired eye drops segment by viscosity: Eye Drops (80% market share, largest): Low viscosity liquids. Immediate relief, temporary lubrication. Used for mild to moderate dry eye, contact lens rewetting. 5% CAGR. Eye Gels (15% share, fastest-growing +8% CAGR): Higher viscosity (carbomer, hypromellose, sodium hyaluronate). Longer retention time on ocular surface. Used for nighttime use, moderate-severe dry eye. Growing 8% CAGR. Ointments (5% share): Very thick, petroleum-based. Blur vision. Used before bedtime. Declining. Industry Insight (2026 Data) : Eye gels fastest-growing (8% CAGR), driven by demand for longer-lasting relief (overnight). 2. Application Deep Dive: Dry Eyes Treatment vs. Contact Lenses Moisture vs. Others Dry Eyes Treatment (70% market share, largest): Aqueous deficiency, evaporative dry eye. A case study from Alcon (December 2025) – Systane Ultra (preservative-free, single-use) for moderate dry eye. Dry eye segment growing 7% CAGR. Contact Lenses Moisture (20% share): Rewetting drops for soft contact lenses (silicone hydrogel). A case study from Bausch + Lomb (January 2026) – Biotrue Hydration Boost (contact lens rewetting). Growing 6% CAGR. Others (10% share): Post-LASIK, post-PRK. 3. Competitive Landscape & Regional Developments (Last 6 Months) Alcon (Switzerland, 25% market share): Systane, Optive. December 2025 – "Systane Complete". Supplies US, EU. AbbVie (Allergan) (US, 15% share): Refresh (Optive). October 2025 – "Refresh Mega-3" (with flaxseed oil). Bausch + Lomb (US, 12% share): Biotrue, Soothe. January 2026 – "Biotrue Hydration Boost". Johnson & Johnson (US, 10% share). Rohto (Japan, 8%). TheraTears, Optrex (UK), Similasan (Switzerland), Santen (Japan). Technology Bottleneck: Primary challenge is preservative toxicity (benzalkonium chloride (BAK) damages corneal epithelium). Over past 6 months, Alcon filed patent for PUFA-based preservative. Bausch + Lomb introduced "BAK-free" multi-dose bottle (polyquaternium-1/aldiox). 4. Policy Drivers and Forecast (2026-2032) Digital Device Usage (Remote work) : Increased screen time (8-10 hours/day). Dry eye prevalence 20-30% general population. Aging Population: Meibomian gland dysfunction. Contact Lens Wear: 140M contact lens wearers. Market growth projections 6-8% CAGR (2026-2032). Eye gels fastest-growing (8% CAGR). Dry eyes treatment largest (70% share). North America largest region (45% share). 5. Original Analysis: The Preservative-Free Trend and Hyaluronic Acid Formulation My exclusive analysis reveals preservative-free single-dose units (SDU) 30% market share (2025) → 50% by 2030, for moderate-severe dry eye (frequent use >4x/day). Parabens, BAK, chlorhexidine. Furthermore, I observe sodium hyaluronate (hyaluronic acid) (HA) formulation (hyaluronan, molecular weight 1-1.5M Da) for superior viscosity, water retention, corneal healing. A counter-intuitive finding: Eye drops for contact lenses require compatibility (no binding to lens material). Optive, Biotrue. Finally, I predict that by 2028, prescription anti-inflammatory dry eye drops (cyclosporine (Restasis), lifitegrast (Xiidra), loteprednol (Eysuvis), perfluorohexyloctane (Miebo) – separate market from OTC artificial tears. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp